| scholarly article | Q13442814 |
| P2093 | author name string | Myron S Czuczman | |
| Qiang Hu | |||
| Francisco J Hernandez-Ilizaliturri | |||
| Cory Mavis | |||
| Juan J Gu | |||
| Matthew J Barth | |||
| Joseph Skitzki | |||
| Liu Song | |||
| Sarah Frys | |||
| Zachary Simons | |||
| P2860 | cites work | Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization | Q37403050 |
| Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma | Q38004217 | ||
| Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. | Q38327984 | ||
| A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). | Q39248784 | ||
| Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines | Q39973753 | ||
| Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression | Q40006309 | ||
| Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis | Q40097403 | ||
| Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels | Q40117375 | ||
| LFA-1 signaling through p44/42 is coupled to perforin degranulation in CD56+CD8+ natural killer cells | Q40561963 | ||
| Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy | Q40634072 | ||
| Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. | Q41762088 | ||
| The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. | Q42163084 | ||
| HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells | Q42945834 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study | Q44875676 | ||
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma | Q45115068 | ||
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma | Q46455509 | ||
| Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al | Q46669969 | ||
| MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. | Q52885667 | ||
| Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. | Q54596898 | ||
| Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity) | Q71010222 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model | Q79367320 | ||
| Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy | Q79835615 | ||
| Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll | Q80199403 | ||
| Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies | Q81310348 | ||
| The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance | Q27118298 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Histone deacetylases and cancer | Q28240447 | ||
| Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer | Q29615649 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| p21 in cancer: intricate networks and multiple activities | Q30436015 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33394023 | ||
| Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. | Q33405714 | ||
| Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity | Q34341016 | ||
| Histone deacetylase inhibitors in Hodgkin lymphoma | Q34414440 | ||
| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group | Q34566901 | ||
| The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. | Q34672100 | ||
| Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma | Q34750551 | ||
| Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo | Q35206717 | ||
| The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. | Q35223868 | ||
| HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL | Q35553330 | ||
| Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours | Q35653852 | ||
| Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias | Q35750919 | ||
| Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma | Q35783537 | ||
| The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. | Q35953399 | ||
| A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. | Q36337623 | ||
| Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. | Q36403556 | ||
| Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy | Q36703116 | ||
| Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a | Q36938662 | ||
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Q37372837 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| entinostat | Q1281020 | ||
| B-cell lymphoma | Q4833719 | ||
| P304 | page(s) | 506-519 | |
| P577 | publication date | 2015-02-23 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents | |
| P478 | volume | 169 |
| Q33689457 | A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC. |
| Q38765451 | An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma |
| Q37144116 | Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling |
| Q89403508 | Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells |
| Q89850073 | Epigenetic Therapy as a Putative Molecular Target to Modulate B Cell Biology and Behavior in the Context of Immunological Disorders |
| Q26744080 | Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies |
| Q92334161 | From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs |
| Q26781247 | Functional Role of G9a Histone Methyltransferase in Cancer |
| Q90254095 | HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma |
| Q38799515 | Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma |
| Q28082536 | Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy |
| Q90322835 | Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies |
| Q64260957 | Therapeutic targeting of immune checkpoints with small molecule inhibitors |
| Q39091822 | Treatment approaches of hard-to-treat non-Hodgkin lymphomas |
Search more.